8-K Announcements
6Material company update
May 6, 2026·SEC
Material company update
Apr 13, 2026·SEC
Material company update
Mar 20, 2026·SEC
EyePoint Pharmaceuticals, Inc.(EYPT)Earnings, Financials & Key Ratios
EYPT•NASDAQ
Price updated Jun 19, 2026
AboutEyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. It also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.Show more
- Revenue$31M-27.5%
- EBITDA-$243M-68.7%
- Net Income-$232M-77.2%
- EPS (Diluted)-3.17-36.6%
- Gross Margin93.41%+2.2%
- EBITDA Margin-775.98%-132.7%
- Operating Margin-775.98%-130.2%
- Net Margin-739.42%-144.5%
- ROE-72.19%-66.3%
EYPT Key Insights
EyePoint Pharmaceuticals, Inc. (EYPT) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
✗Weaknesses
- ✗Profits declining 38.6% over 5 years
- ✗Weak Piotroski F-Score: 2/9
- ✗Negative free cash flow
- ✗Shares diluted 30.1% in last year
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when EYPT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
EYPT Price & Volume
EyePoint Pharmaceuticals, Inc. (EYPT) stock price & volume — 10-year historical chart
Loading chart...
EYPT Growth Metrics
EyePoint Pharmaceuticals, Inc. (EYPT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years1.68%
5 Years-1.85%
3 Years-8.83%
TTM-86.41%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-85.04%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-45.23%
Return on Capital
10 Years-62.91%
5 Years-46.99%
3 Years-49.44%
Last Year-69.91%
EYPT Recent Earnings
EyePoint Pharmaceuticals, Inc. (EYPT) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 2/12 qtrs (17%)●Beat Revenue 7/12 qtrs (58%)
Q2 2026Latest
May 6, 2026Metric
Actual
Est
EPS
$0.99-25.3%
$0.79
Rev
$696,000+97.3%
$352,833
Q2 2026
Mar 4, 2026Metric
Actual
Est
EPS
$0.81-3.8%
$0.78
Rev
$620,000-37.7%
$994,464
Q4 2025
Nov 5, 2025Metric
Actual
Est
EPS
$0.85-10.4%
$0.77
Rev
$966,000-4.0%
$1M
Q3 2025
Aug 6, 2025Metric
Actual
Est
EPS
$0.85-26.9%
$0.67
Rev
$5M+29.2%
$4M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 6, 2026 | $0.99vs $0.79-25.3% | $696,000vs $352,833+97.3% |
| Q2 2026 | Mar 4, 2026 | $0.81vs $0.78-3.8% | $620,000vs $994,464-37.7% |
| Q4 2025 | Nov 5, 2025 | $0.85vs $0.77-10.4% | $966,000vs $1M-4.0% |
| Q3 2025 | Aug 6, 2025 | $0.85vs $0.67-26.9% | $5Mvs $4M+29.2% |
Based on last 12 quarters of dataView full earnings history →
EYPT Peer Comparison
EyePoint Pharmaceuticals, Inc. (EYPT) competitors in Ophthalmology Therapies and Delivery — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 OCUL | 2.06B | 9.43 | -6.64 | -18.67% | -5.58% | -64.55% | 0.12 | |
 RCKT | 365.8M | 3.35 | -1.67 | -70.79% | 0.09 | |||
 ALDX | 118.23M | 1.96 | -3.50 | -0% | 0.35 | |||
 KALA | 79.17M | 3.61 | -1.09 | -13.36% | ||||
 NVCR | 1.62B | 14.28 | -11.70 | 8.28% | -25.66% | -50.82% | 0.85 | |
 AVXL | 252.99M | 2.73 | -5.06 | -38.76% | ||||
 REGN | 63.37B | 609.94 | 14.70 | 0.99% | 29.65% | 14.32% | 0.09 | |
 AGIO | 2.03B | 34.16 | -4.80 | 48.03% | -6.4% | -34.11% | 0.05 |
Compare EYPT vs Peers
EyePoint Pharmaceuticals, Inc. (EYPT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
EYPT Income Statement
EyePoint Pharmaceuticals, Inc. (EYPT) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Jun'17 | Jun'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 7.54M | 2.96M | 20.36M | 34.44M | 36.94M | 41.4M | 46.02M | 43.27M | 31.37M | 7.62M |
Revenue Growth % | 365.37% | -60.72% | 587.77% | 69.1% | 7.27% | 12.09% | 11.14% | -5.97% | -27.5% | -86.41% |
Cost of Goods Sold | 0 | 18.5M | 2.69M | 5.82M | 8.18M | 8.33M | 4.63M | 3.71M | 2.07M | 1.79M |
COGS % of Revenue | - | 624.86% | 13.19% | 16.91% | 22.14% | 20.11% | 10.07% | 8.58% | 6.59% | - |
Gross Profit | 7.54M▲ 0% | -15.54M▼ 306.1% | 17.68M▲ 213.8% | 28.61M▲ 61.9% | 28.76M▲ 0.5% | 33.08M▲ 15.0% | 41.39M▲ 25.1% | 39.56M▼ 4.4% | 29.3M▼ 25.9% | 5.83M▲ 0% |
Gross Margin % | 100% | -524.86% | 86.81% | 83.09% | 77.86% | 79.89% | 89.93% | 91.42% | 93.41% | 76.51% |
Gross Profit Growth % | 836.52% | -306.14% | 213.75% | 61.86% | 0.52% | 15.01% | 25.12% | -4.41% | -25.92% | - |
Operating Expenses | 26.11M | 29.23M | 65.54M | 65.9M | 84.04M | 132.72M | 116.45M | 185.41M | 272.74M | 287.65M |
OpEx % of Revenue | 346.4% | 987.34% | 321.82% | 191.37% | 227.5% | 320.54% | 253.06% | 428.48% | 869.4% | - |
Selling, General & Admin | 11.23M | 13.06M | 47.71M | 46.02M | 53.08M | 60.32M | 51.79M | 52.49M | 51.7M | 53.03M |
SG&A % of Revenue | 149.03% | 440.97% | 234.28% | 133.63% | 143.69% | 145.7% | 112.55% | 121.3% | 164.8% | - |
Research & Development | 14.88M | 16.18M | 15.37M | 17.42M | 28.5M | 49.64M | 64.66M | 132.93M | 221.04M | 234.61M |
R&D % of Revenue | 197.37% | 546.37% | 75.46% | 50.6% | 77.15% | 119.9% | 140.51% | 307.18% | 704.6% | - |
Other Operating Expenses | 0 | 14.84M | 2.46M | 2.46M | 2.46M | 22.75M | 0 | 0 | 0 | 0 |
Operating Income | -18.58M▲ 0% | -26.27M▼ 41.4% | -47.86M▼ 82.2% | -37.29M▲ 22.1% | -55.28M▼ 48.2% | -99.64M▼ 80.3% | -75.07M▲ 24.7% | -145.85M▼ 94.3% | -243.43M▼ 66.9% | -281.82M▲ 0% |
Operating Margin % | -246.4% | -887.34% | -235.02% | -108.28% | -149.64% | -240.65% | -163.13% | -337.06% | -775.98% | -3700.89% |
Operating Income Growth % | 14.69% | -41.44% | -82.16% | 22.09% | -48.23% | -80.25% | 24.66% | -94.3% | -66.9% | - |
EBITDA | -17.76M | -23.62M | -45.26M | -34.64M | -52.51M | -97.19M | -74.6M | -144.31M | -243.43M | -280.71M |
EBITDA Margin % | -235.59% | -797.77% | -222.23% | -100.59% | -142.14% | -234.74% | -162.12% | -333.5% | -775.98% | -3686.26% |
EBITDA Growth % | 15.26% | -33% | -91.59% | 23.46% | -51.57% | -85.11% | 23.24% | -93.44% | -68.68% | -75.84% |
D&A (Non-Cash Add-back) | 815K | 2.65M | 2.6M | 2.65M | 2.77M | 2.45M | 464K | 1.54M | 0 | 1.11M |
EBIT | -52.45M | -39.02M | -50.62M | -38.14M | -52.92M | -99.06M | -69.47M | -130.77M | -243.43M | -279.53M |
Net Interest Income | -619K | -619K | -5.12M | -7.2M | -5.21M | -1.06M | 5.7M | 15.07M | 11.75M | 10.45M |
Interest Income | 91K | 101K | 1.05M | 58K | 292K | 2.13M | 6.95M | 15.09M | 11.75M | 10.45M |
Interest Expense | 720K | 720K | 6.18M | 7.26M | 5.5M | 3.19M | 1.25M | 14K | -33K | 0 |
Other Income/Expense | -26.9M | -63.17M | -8.93M | -8.1M | -3.14M | -2.62M | 4.36M | 15.07M | 11.75M | 10.45M |
Pretax Income | -18.48M▲ 0% | -53.17M▼ 187.6% | -56.79M▼ 6.8% | -45.39M▲ 20.1% | -58.42M▼ 28.7% | -102.25M▼ 75.0% | -70.71M▲ 30.8% | -130.78M▼ 84.9% | -231.68M▼ 77.2% | -271.37M▲ 0% |
Pretax Margin % | -245.19% | -1795.71% | -278.88% | -131.82% | -158.14% | -246.97% | -153.66% | -302.22% | -738.53% | -3563.62% |
Income Tax | -815K | -25.56M | 0 | 0 | 0 | 0 | 83K | 90K | 279K | -43K |
Effective Tax Rate % | 4.41% | 48.07% | 0% | 0% | 0% | 0% | -0.12% | -0.07% | -0.12% | 0.02% |
Net Income | -18.48M▲ 0% | -53.17M▼ 187.6% | -56.79M▼ 6.8% | -45.39M▲ 20.1% | -58.42M▼ 28.7% | -102.25M▼ 75.0% | -70.8M▲ 30.8% | -130.87M▼ 84.9% | -231.96M▼ 77.2% | -271.6M▲ 0% |
Net Margin % | -245.19% | -1795.71% | -278.88% | -131.82% | -158.14% | -246.97% | -153.84% | -302.43% | -739.42% | -3566.63% |
Net Income Growth % | 14.21% | -187.64% | -6.81% | 20.07% | -28.69% | -75.04% | 30.77% | -84.86% | -77.25% | -85.04% |
Net Income (Continuing) | -53.17M | -89.44M | -56.79M | -45.39M | -58.42M | -102.25M | -70.8M | -130.87M | -231.96M | -271.33M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -5.23▲ 0% | -11.50▼ 119.9% | -6.04▲ 47.5% | -3.54▲ 41.4% | -2.03▲ 42.7% | -2.74▼ 35.0% | -1.82▲ 33.6% | -2.32▼ 27.5% | -3.17▼ 36.6% | -3.16▲ 0% |
EPS Growth % | 23.2% | -119.89% | 47.48% | 41.39% | 42.66% | -34.98% | 33.58% | -27.47% | -36.64% | -45.23% |
EPS (Basic) | -5.23 | -11.50 | -6.04 | -3.54 | -2.03 | -2.74 | -1.82 | -2.32 | -3.17 | - |
Diluted Shares Outstanding | 3.53M | 4.62M | 10.43M | 12.84M | 28.76M | 37.32M | 38.9M | 56.3M | 73.25M | 86M |
Basic Shares Outstanding | 3.53M | 4.62M | 10.43M | 12.84M | 28.76M | 37.32M | 38.9M | 56.3M | 73.25M | 86M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
EYPT Balance Sheet
EyePoint Pharmaceuticals, Inc. (EYPT) balance sheet — assets, liabilities & shareholders' equity
| Metric | Jun'17 | Jun'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 17.74M | 39.91M | 41.72M | 63.12M | 237.75M | 172.81M | 344.8M | 383.31M | 328.65M | 249.5M |
Cash & Short-Term Investments | 16.9M | 38.78M | 22.21M | 44.91M | 211.56M | 144.56M | 331.05M | 370.91M | 306.09M | 222.54M |
Cash Only | 16.9M | 38.78M | 22.21M | 44.91M | 178.59M | 95.63M | 281.26M | 99.7M | 101.82M | 77.71M |
Short-Term Investments | 0 | 0 | 0 | 0 | 32.97M | 48.93M | 49.79M | 271.21M | 204.26M | 144.83M |
Accounts Receivable | 353K | 353K | 11.37M | 9.45M | 18.35M | 15.5M | 805K | 607K | 651K | 1.16M |
Days Sales Outstanding | 17.09 | 43.51 | 203.75 | 100.19 | 181.36 | 136.67 | 6.38 | 5.12 | 7.57 | 41.68 |
Inventory | -251K | -353K | 2.14M | 5.34M | 3.62M | 2.89M | 3.91M | 2.31M | 1.81M | 1.25M |
Days Inventory Outstanding | - | - | 290.42 | 334.48 | 161.41 | 126.52 | 307.79 | 226.65 | 320.3 | 400.45 |
Other Current Assets | 0 | 1.13M | 0 | 0 | 517K | 782K | 1.01M | 1.41M | 20.11M | 24.55M |
Total Non-Current Assets | 937K | 31.76M | 31.25M | 28.6M | 25.63M | 7.55M | 10.38M | 35.16M | 35.34M | 38.71M |
Property, Plant & Equipment | 313K | 253K | 3.44M | 3.24M | 2.73M | 7.4M | 10.23M | 29.18M | 20.22M | 19.78M |
Fixed Asset Turnover | 24.09x | 11.70x | 5.93x | 10.63x | 13.54x | 5.60x | 4.50x | 1.48x | 1.55x | 0.34x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 364K | 31.36M | 27.67M | 25.21M | 22.75M | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 150K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 260K | 150K | 150K | 150K | 150K | 150K | 150K | 5.98M | 15.12M | 18.94M |
Total Assets | 18.68M▲ 0% | 71.67M▲ 283.7% | 72.97M▲ 1.8% | 91.72M▲ 25.7% | 263.37M▲ 187.2% | 180.36M▼ 31.5% | 355.18M▲ 96.9% | 418.46M▲ 17.8% | 364M▼ 13.0% | 288.22M▲ 0% |
Asset Turnover | 0.40x | 0.04x | 0.28x | 0.38x | 0.14x | 0.23x | 0.13x | 0.10x | 0.09x | 0.03x |
Asset Growth % | -40.93% | 283.73% | 1.82% | 25.69% | 187.16% | -31.52% | 96.94% | 17.82% | -13.02% | -57% |
Total Current Liabilities | 5.29M | 21.66M | 11.52M | 14.89M | 23.66M | 34.54M | 63.26M | 49.05M | 37.02M | 37.46M |
Accounts Payable | 2.94M | 2.64M | 4.19M | 4.81M | 7.38M | 5.92M | 6.5M | 11.72M | 34.88M | 35.25M |
Days Payables Outstanding | - | 52.08 | 569.44 | 301.51 | 329.65 | 259.48 | 512.51 | 1.15K | 6.16K | 6.6K |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 10.47M | 0 | 0 | 0 | 0 |
Deferred Revenue (Current) | 50K | 30K | 15K | 945K | 1.07M | 1.21M | 38.59M | 17.78M | 0 | 0 |
Other Current Liabilities | -14.61M | 15M | 3.26M | 5.69M | 7.32M | 9.52M | 13.28M | 13.27M | 2.14M | 2.21M |
Current Ratio | 3.35x | 1.84x | 3.62x | 4.24x | 10.05x | 5.00x | 5.45x | 7.81x | 8.88x | 6.66x |
Quick Ratio | 3.40x | 1.86x | 3.44x | 3.88x | 9.90x | 4.92x | 5.39x | 7.77x | 8.83x | 6.63x |
Cash Conversion Cycle | - | - | -75.27 | 133.16 | 13.12 | 3.71 | -198.34 | -920.75 | -5.84K | -6.15K |
Total Non-Current Liabilities | 51K | 38.32M | 53.12M | 58.29M | 55.33M | 49.45M | 25.6M | 32.92M | 20.86M | 20.28M |
Long-Term Debt | 17.31M | 17.31M | 47.22M | 37.98M | 36.56M | 29.31M | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 0 | 0 | 2.9M | 2.33M | 1.86M | 5.98M | 4.91M | 21.86M | 20.77M | 84.12M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | -17.26M | 21.01M | 3M | 2.37M | 2.35M | 600K | 0 | 205K | 87K | 55K |
Total Liabilities | 5.34M | 59.98M | 64.64M | 73.18M | 78.99M | 83.99M | 88.86M | 81.96M | 57.88M | 57.74M |
Total Debt | 17.31M | 17.31M | 50.6M | 40.99M | 39.2M | 46.35M | 4.91M | 21.86M | 20.77M | 20.23M |
Net Debt | 411K | -21.47M | 28.39M | -3.92M | -139.39M | -49.28M | -276.36M | -77.85M | -81.05M | -57.48M |
Debt / Equity | 1.30x | 1.48x | 6.07x | 2.21x | 0.21x | 0.48x | 0.02x | 0.06x | 0.07x | 0.09x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.07x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.20x |
Interest Coverage | -72.85x | -54.19x | -8.20x | -5.26x | -9.63x | -31.06x | -55.71x | -9340.43x | -7376.79x | - |
Total Equity | 13.34M▲ 0% | 11.69M▼ 12.4% | 8.33M▼ 28.7% | 18.54M▲ 122.6% | 184.38M▲ 894.4% | 96.37M▼ 47.7% | 266.32M▲ 176.4% | 336.5M▲ 26.4% | 306.11M▼ 9.0% | 230.47M▲ 0% |
Equity Growth % | -36.13% | -12.37% | -28.72% | 122.58% | 894.44% | -47.73% | 176.36% | 26.35% | -9.03% | -32.52% |
Book Value per Share | 3.77 | 2.53 | 0.80 | 1.44 | 6.41 | 2.58 | 6.85 | 5.98 | 4.18 | 2.68 |
Total Shareholders' Equity | 13.34M | 11.69M | 8.33M | 18.54M | 184.38M | 96.37M | 266.32M | 336.5M | 306.11M | 230.47M |
Common Stock | 323.32M | 374.84M | 11K | 18K | 34K | 34K | 49K | 68K | 1.41B | 1.42B |
Retained Earnings | -310.82M | -363.99M | -465.29M | -510.68M | -569.1M | -671.35M | -742.15M | -873.02M | -1.1B | -1.19B |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 833K | 838K | 840K | 841K | 841K | 786K | 864K | 1.03M | 961K | 802K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EYPT Cash Flow Statement
EyePoint Pharmaceuticals, Inc. (EYPT) cash flow — operating, investing & free cash flow history
| Metric | Jun'17 | Jun'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -20.49M | -21.91M | -56.7M | -14.44M | -50.1M | -65M | 1.88M | -126.23M | -240.11M | -186.99M |
Operating CF Margin % | -271.79% | -739.85% | -278.41% | -41.92% | -135.62% | -157% | 4.07% | -291.7% | -765.39% | - |
Operating CF Growth % | -25.58% | -6.92% | -158.82% | 74.54% | -247.05% | -29.76% | 102.88% | -6832.05% | -90.22% | -243.71% |
Net Income | -18.48M | -53.17M | -56.79M | -45.39M | -58.42M | -102.25M | -70.8M | -130.87M | -231.96M | -271.6M |
Depreciation & Amortization | 815K | 1.15M | 2.6M | 2.65M | 2.77M | 2.45M | 464K | 1.54M | 2.31M | 1.81M |
Stock-Based Compensation | 2.7M | 3.97M | 4.57M | 5.55M | 7.45M | 14.18M | 12.06M | 36.74M | 27.87M | 20.05M |
Deferred Taxes | 0 | 26.28M | 3.81M | 905K | -787K | 0 | 83K | 90K | 279K | 369K |
Other Non-Cash Items | -5.59M | 209K | 1.65M | 1.72M | 628K | 23.65M | 1.18M | -5.95M | -4.83M | 81.65M |
Working Capital Changes | 318K | 925K | -12.54M | 20.14M | -1.74M | -3.02M | 58.88M | -27.77M | -33.78M | -19.27M |
Change in Receivables | 219K | 7K | -15.3M | 4.85M | -10.6M | -2.66M | 14.43M | -244K | -10.67M | -14.1M |
Change in Inventory | 551K | -759K | -1.86M | -3.2M | 1.35M | -760K | -1.55M | 1.6M | 492K | 316K |
Change in Payables | -346K | 1.75M | 4.6M | 1.87M | 8.48M | 1.2M | 1.52M | 5.73M | 4.68M | -297K |
Cash from Investing | 13.58M | -16.89M | -213K | -362K | -33.12M | -17.27M | -3.31M | -219.35M | 68.58M | 29.05M |
Capital Expenditures | -147K | -108K | -213K | -362K | -156K | -2.15M | -3.48M | -4.05M | -3.28M | -3M |
CapEx % of Revenue | 1.95% | 3.65% | 1.05% | 1.05% | 0.42% | 5.19% | 7.57% | 9.36% | 10.46% | 39.45% |
Acquisitions | -16.78M | -16.78M | 0 | 0 | 0 | -558K | -168K | 0 | 155K | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 33K | 0 | 0 | 0 | 0 | 558K | 168K | 5.95M | 4.83M | 316K |
Cash from Financing | 8.5M | 60.67M | 33.86M | 37.49M | 216.9M | -690K | 187.07M | 164.02M | 173.65M | 174.6M |
Debt Issued (Net) | 20M | 20M | 30M | -11.8M | -146K | 2.1M | -40.51M | -105K | -105K | -70K |
Equity Issued (Net) | 41.52M | 29.4M | -120K | 49.92M | 216.82M | 395K | 226.17M | 163.31M | 175.14M | 174.55M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | -195K | 0 | 0 | 0 | -295K | 0 | 0 | 0 | 0 |
Other Financing | -844K | -20.2M | 3.98M | -624K | 223K | -3.19M | 1.41M | 813K | -1.39M | 121K |
Net Change in Cash | 1.58M▲ 0% | 21.88M▲ 1280.3% | -23.05M▼ 205.3% | 22.7M▲ 198.5% | 133.68M▲ 489.0% | -82.96M▼ 162.1% | 185.63M▲ 323.8% | -181.56M▼ 197.8% | 2.12M▲ 101.2% | -7.45M▲ 0% |
Free Cash Flow | -20.64M▲ 0% | -22.02M▼ 6.7% | -56.91M▼ 158.5% | -14.8M▲ 74.0% | -50.25M▼ 239.6% | -67.16M▼ 33.6% | -1.61M▲ 97.6% | -130.28M▼ 8001.9% | -243.39M▼ 86.8% | -189.99M▲ 0% |
FCF Margin % | -273.74% | -743.5% | -279.46% | -42.97% | -136.04% | -162.19% | -3.49% | -301.06% | -775.84% | -2495% |
FCF Growth % | -25.61% | -6.68% | -158.51% | 74% | -239.62% | -33.63% | 97.61% | -8001.87% | -86.82% | -25.57% |
FCF per Share | -5.84 | -4.76 | -5.46 | -1.15 | -1.75 | -1.80 | -0.04 | -2.31 | -3.32 | -2.21 |
FCF Conversion (FCF/Net Income) | 1.11x | 0.41x | 1.00x | 0.32x | 0.86x | 0.64x | -0.03x | 0.96x | 1.04x | 0.70x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 2.6M | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 600K | 0 | 0 | 0 | 0 |
EYPT Key Ratios
EyePoint Pharmaceuticals, Inc. (EYPT) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -108.05% | -424.98% | -567.45% | -337.87% | -57.58% | -72.84% | -39.04% | -43.42% | -72.19% | -110.54% |
Return on Invested Capital (ROIC) | -144.26% | -993.47% | -266.51% | -108.94% | -139.08% | -162.32% | -303.92% | -88% | -75.49% | -114% |
Gross Margin | 100% | -524.86% | 86.81% | 83.09% | 77.86% | 79.89% | 89.93% | 91.42% | 93.41% | 76.51% |
Net Margin | -245.19% | -1795.71% | -278.88% | -131.82% | -158.14% | -246.97% | -153.84% | -302.43% | -739.42% | -3566.63% |
Debt / Equity | 1.30x | 1.48x | 6.07x | 2.21x | 0.21x | 0.48x | 0.02x | 0.06x | 0.07x | 0.09x |
Interest Coverage | -72.85x | -54.19x | -8.20x | -5.26x | -9.63x | -31.06x | -55.71x | -9340.43x | -7376.79x | - |
FCF Conversion | 1.11x | 0.41x | 1.00x | 0.32x | 0.86x | 0.64x | -0.03x | 0.96x | 1.04x | 0.70x |
Revenue Growth | 365.37% | -60.72% | 587.77% | 69.1% | 7.27% | 12.09% | 11.14% | -5.97% | -27.5% | -86.41% |
Related:EYPT Dividend History·EYPT Revenue History·EYPT Price History·EYPT P/E History·EYPT Financial Ratios·EYPT Institutional Holders
EYPT SEC Filings & Documents
EyePoint Pharmaceuticals, Inc. (EYPT) SEC filings — annual & quarterly reports (10-K, 10-Q)
EYPT Frequently Asked Questions
EyePoint Pharmaceuticals, Inc. (EYPT) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
EyePoint Pharmaceuticals, Inc. (EYPT) reported $7.6M in revenue for fiscal year 2025. This represents a 10142% increase from $0.1M in 2003.
EyePoint Pharmaceuticals, Inc. (EYPT) saw revenue decline by 27.5% over the past year.
EyePoint Pharmaceuticals, Inc. (EYPT) reported a net loss of $271.6M for fiscal year 2025.
Dividend & Returns
EyePoint Pharmaceuticals, Inc. (EYPT) has a return on equity (ROE) of -72.2%. Negative ROE indicates the company is unprofitable.
EyePoint Pharmaceuticals, Inc. (EYPT) had negative free cash flow of $190.0M in fiscal year 2025, likely due to heavy capital investments.